B Group, Inc. 89bio, Inc. Transaction History
B Group, Inc.
- $117 Billion
- Q1 2025
A detailed history of B Group, Inc. transactions in 89bio, Inc. stock. As of the latest transaction made, B Group, Inc. holds 95,623 shares of ETNB stock, worth $923,718. This represents 0.6% of its overall portfolio holdings.
Number of Shares
95,623Holding current value
$923,718% of portfolio
0.6%Shares
1 transactions
Others Institutions Holding ETNB
# of Institutions
208Shares Held
158MCall Options Held
366KPut Options Held
944K-
Janus Henderson Group PLC London, X020.5MShares$198 Million0.09% of portfolio
-
Ra Capital Management, L.P. Boston, MA19.9MShares$192 Million3.0% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.3MShares$138 Million4.56% of portfolio
-
Deep Track Capital, LP Greenwich, CT9.32MShares$90 Million2.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.16MShares$69.2 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $449M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...